Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05535361 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 5
    • Start date: Sep 15, 2025 to Sep 15, 2023
    • Collaborators: 7 to 6
    v7
  2. Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
    • Study sites: 4 to 6
    • Eligibility criteria revised
    • Study description revised
    • Collaborators: 5 to 7
  3. Enrollment target: 15 to 40v5 Show 8 more changesShow less
    • Primary completion date: Dec 2025 to Mar 1, 2028
    • Start date: Jan 15, 2023 to Sep 15, 2025
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Jun 2026 to Jun 30, 2028
    • Eligibility criteria shortened, about 43 words
    • Secondary endpoints: 1 to 2
    • Study description expanded, about 24 words
    • Site details revised at 4 of 4 sites
  4. Study sites: 1 to 4
    • Collaborators: 4 to 5
    v4
  5. Primary completion date: Dec 2024 to Dec 2025v3 Show 7 more changesShow less
    • Enrollment target: 18 to 15
    • Study completion date: Jan 2025 to Jun 2026
    • Study description expanded, about 20 words
    • Site contact updated
    • Collaborators expanded, about 22 words
    • Study title expanded, about 9 words
    • Eligibility criteria expanded, about 1 word
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Oct 2023 to Dec 2024
    • Study sites: 0 to 1
    • Study completion date: Jan 2024 to Jan 2025
    • Start date changed from estimate of Oct 2022 to Jan 15, 2023
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
Trial Details
NCT Number NCT05535361
Lead Sponsor Eclipse Regenesis, Inc.
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Children's Hospital Medical Center, Cincinnati, University of California, San Francisco, Boston Children's Hospital, Lucile Packard Children's Hospital at Stanford, Children's National Health System, Washington DC
Conditions
(from sponsor)		 Short Bowel Syndrome
Related terms Enterocolitis, Necrotizing, Intestinal Atresia, Intestinal Failure, Intestinal Volvulus, Short Bowel Syndrome
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov